Published in Cancer Res on October 15, 1987
Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol (2008) 2.81
The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays. Mol Cell Proteomics (2009) 1.77
Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma. Ann Surg (1992) 1.55
Pancreatic adenocarcinoma. J Natl Compr Canc Netw (2010) 1.52
The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol (2012) 1.46
Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol (2010) 1.38
The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma. Dig Dis Sci (2011) 1.30
The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Curr Mol Med (2013) 1.21
Screening for pancreatic cancer: why, how, and who? Ann Surg (2013) 1.19
Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer. Br J Cancer (1994) 1.11
Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei Med J (2013) 1.07
Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers. PLoS One (2011) 1.07
Advances in biomarker research for pancreatic cancer. Curr Pharm Des (2012) 1.05
CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol (2010) 1.00
CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer (2009) 0.98
Strategies for discovering novel pancreatic cancer biomarkers. J Proteomics (2012) 0.96
Serum HSP70: a novel biomarker for early detection of pancreatic cancer. Pancreas (2012) 0.95
Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One (2011) 0.95
Pancreatic Cancer Database: an integrative resource for pancreatic cancer. Cancer Biol Ther (2014) 0.94
Diverse monoclonal antibodies against the CA 19-9 antigen show variation in binding specificity with consequences for clinical interpretation. Proteomics (2012) 0.94
Neoadjuvant therapy for pancreas cancer: past lessons and future therapies. World J Gastroenterol (2014) 0.93
Borderline resectable pancreatic cancer: definitions and management. World J Gastroenterol (2014) 0.92
Comparing human pancreatic cell secretomes by in vitro aptamer selection identifies cyclophilin B as a candidate pancreatic cancer biomarker. J Clin Invest (2012) 0.92
Molecular markers of pancreatic cancer: development and clinical relevance. Langenbecks Arch Surg (2008) 0.91
Combination of the serum carbohydrate antigen 19-9 and carcinoembryonic antigen is a simple and accurate predictor of mortality in pancreatic cancer patients. Surg Today (2013) 0.89
A Novel Multivariate Index for Pancreatic Cancer Detection Based On the Plasma Free Amino Acid Profile. PLoS One (2015) 0.88
Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br J Cancer (2014) 0.87
Risk factors for pancreatic adenocarcinoma and prospects for screening. Gastroenterol Hepatol (N Y) (2010) 0.86
CA 19-9 and pancreatic cancer. Clin Adv Hematol Oncol (2013) 0.86
Factors affecting long-term survival after surgical resection of pancreatic ductal adenocarcinoma. J Korean Surg Soc (2011) 0.86
The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma. Ann Surg Oncol (2014) 0.85
Elevated baseline CA19-9 levels correlate with adverse prognosis in patients with early- or advanced-stage pancreas cancer. Med Oncol (2012) 0.84
CA 19-9 as a serum marker in urothelial carcinoma. Urol Ann (2012) 0.84
Intensity of follow-up after pancreatic cancer resection. Ann Surg Oncol (2013) 0.83
Rapid characterization of candidate biomarkers for pancreatic cancer using cell microarrays (CMAs). J Proteome Res (2012) 0.83
The Microbiome and Cancer: Is the 'Oncobiome' Mirage Real? Trends Cancer (2015) 0.80
Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study. World J Surg Oncol (2014) 0.79
Serum level of Ca 19-9 increases ability of IgG4 test to distinguish patients with autoimmune pancreatitis from those with pancreatic carcinoma. Dig Dis Sci (2014) 0.78
A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain shedding. PLoS One (2014) 0.78
Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Oncotarget (2016) 0.76
Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) (2015) 0.76
Chromodomain-helicase-DNA binding protein 5, 7 and pronecrotic mixed lineage kinase domain-like protein serve as potential prognostic biomarkers in patients with resected pancreatic adenocarcinomas. World J Gastrointest Oncol (2016) 0.75
The CA19-9 and Sialyl-TRA Antigens Define Separate Subpopulations of Pancreatic Cancer Cells. Sci Rep (2017) 0.75
The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma. BMC Cancer (2016) 0.75
Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma. Cancer Biol Ther (2015) 0.75
ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Medicine (Baltimore) (2016) 0.75
Positron emission tomography (PET) as a predictive measure in patients with metastatic pancreatic cancer and normal CA19-9 levels at baseline. Ann Oncol (2016) 0.75
Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther (2017) 0.75
Pancreatic Cancer: a Challenge to Cure. Indian J Surg (2015) 0.75
Patients with normal-range CA19-9 levels represent a distinct subgroup of pancreatic cancer patients. Oncol Lett (2016) 0.75
Serum CA19-9 in patients with solid pancreatic mass. Gastroenterol Hepatol Bed Bench (2013) 0.75
Neoadjuvant radiotherapeutic strategies in pancreatic cancer. World J Gastrointest Oncol (2016) 0.75
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis. Onco Targets Ther (2017) 0.75
Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet (1979) 7.28
Activation of production of infectious tumor virus SV40 in heterokaryon cultures. Proc Natl Acad Sci U S A (1967) 6.05
Study of antibodies against human melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A (1978) 4.24
A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem (1982) 3.97
Specific antigen in serum of patients with colon carcinoma. Science (1981) 3.68
Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A (1979) 3.46
Prevention of pancreatic cancer induction in hamsters by metformin. Gastroenterology (2001) 3.38
STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. Mol Cell Biol (1997) 3.18
Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res (1983) 3.15
The gene mutated in ataxia-ocular apraxia 1 encodes the new HIT/Zn-finger protein aprataxin. Nat Genet (2001) 3.01
IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. Mol Ther (2000) 2.59
Purification and properties of H+-translocating, Mg2+-adenosine triphosphatase from vacuolar membranes of Saccharomyces cerevisiae. J Biol Chem (1985) 2.54
Production of human hybridomas secreting antibodies to measles virus. Nature (1980) 2.32
Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet (1982) 2.25
Gastrointestinal cancer-associated antigen in immunoperoxidase assay. Cancer Res (1982) 2.21
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
A monosialoganglioside is a monoclonal antibody-defined antigen of colon carcinoma. Science (1981) 2.02
Cardiac troponin I in calves with congenital heart disease. J Vet Intern Med (2012) 1.97
Immortalization with telomerase of the Nestin-positive cells of the human pancreas. Biochem Biophys Res Commun (2003) 1.93
Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer (2008) 1.93
Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J Med Chem (1998) 1.88
Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells. Science (1983) 1.78
Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma. J Clin Immunol (1982) 1.76
Inhibition of growth of colorectal carcinoma in nude mice by monoclonal antibody. Cancer Res (1980) 1.70
Diagnosis and treatment of biliary tract complications after orthotopic liver transplantation. Surgery (1989) 1.66
Peptide mimicry of carbohydrate epitopes on human immunodeficiency virus. Nat Biotechnol (1997) 1.61
Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol (1979) 1.59
Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci U S A (1990) 1.57
Albumin and nonprotein colloid solution use in US academic health centers. Arch Intern Med (1996) 1.56
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.54
Fasciitis and myositis: an analysis of muscle-related complications caused by chronic GVHD after allo-SCT. Bone Marrow Transplant (2008) 1.49
Optimization of transcriptional regulatory elements for constructing plasmid vectors. Gene (2001) 1.49
Rescue of infectious SV40 after fusion between dfferent SV 40-transformed cells. Proc Natl Acad Sci U S A (1968) 1.43
Hyperplastic, preneoplastic and neoplastic lesions found in 83 human pancreases. Am J Clin Pathol (1982) 1.42
Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod (1984) 1.41
Monoclonal antibodies directed against the human Leb blood group antigen. J Biol Chem (1981) 1.38
Molecular cloning of cDNA for the human tumor-associated antigen CO-029 and identification of related transmembrane antigens. Proc Natl Acad Sci U S A (1990) 1.35
The mechanism of internuclear transmission of SV40-induced complement fixation antigen in heterokaryocytes. Proc Natl Acad Sci U S A (1968) 1.35
Production of monoclonal antibodies in serum free medium. J Immunol Methods (1980) 1.33
Current knowledge of pancreatic carcinogenesis in the hamster and its relevance to the human disease. Cancer (1981) 1.33
Monoclonal antibody detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients with colorectal cancer. J Clin Immunol (1982) 1.31
Primary melanoma cells of the vertical growth phase: similarities to metastatic cells. J Natl Cancer Inst (1985) 1.30
Enhanced expression of annexin II in human pancreatic carcinoma cells and primary pancreatic cancers. Carcinogenesis (1993) 1.30
Specific immunoreactivity of hybridoma-secreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived human cells. Cancer Res (1980) 1.27
Moiré topography. Appl Opt (1970) 1.23
Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst (1989) 1.23
Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis. Proc Natl Acad Sci U S A (1984) 1.23
Expression of blood group-related antigens ABH, Lewis A, Lewis B, Lewis X, Lewis Y, and CA 19-9 in pancreatic cancer cells in comparison with the patient's blood group type. Cancer Res (1988) 1.22
The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol (1985) 1.21
Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A (2000) 1.19
Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma (1983) 1.18
Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab Invest (1984) 1.18
Do shorter-acting neuromuscular blocking drugs or opioids associate with reduced intensive care unit or hospital lengths of stay after coronary artery bypass grafting? CABG Clinical Benchmarking Data Base Participants. Anesthesiology (1998) 1.17
Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther (1991) 1.16
Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology (2007) 1.16
Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res (1985) 1.15
Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med (1994) 1.14
CAR- or alphav integrin-binding ablated adenovirus vectors, but not fiber-modified vectors containing RGD peptide, do not change the systemic gene transfer properties in mice. Gene Ther (2002) 1.14
Shunt surgery versus endoscopic sclerotherapy for long-term treatment of variceal bleeding. Early results of a randomized trial. Ann Surg (1987) 1.13
Tumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effects. Cancer Res (1987) 1.13
Role of uppermost superficial surface layer of articular cartilage in the lubrication mechanism of joints. J Anat (2001) 1.12
Utilization of long chain fatty acids by rat liver: studies of the role of fatty acid binding protein. Gastroenterology (1979) 1.12
Biochemical characterization of human melanoma cell surfaces: dissection with monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 1.12
Shunt surgery versus endoscopic sclerotherapy for variceal hemorrhage: late results of a randomized trial. Am J Surg (1993) 1.11
Reactivity of monoclonal anti-melanoma antibodies with melanoma cells freshly isolated from primary and metastatic melanoma. Eur J Immunol (1979) 1.10
A method for studying isolated resistance vessels from rabbit mesentery and brain and their responses to drugs. Circ Res (1967) 1.10
Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461. Atherosclerosis (1995) 1.10
Purification of yeast vacuolar membrane H+-ATPase and enzymological discrimination of three ATP-driven proton pumps in Saccharomyces cerevisiae. Methods Enzymol (1988) 1.08
Hypothesis: macrophages as effector cells for human tumor destruction mediated by monoclonal antibody. Hybridoma (1983) 1.07
Assessment of central, peripheral, and autonomic nervous system functions in lead workers: neuroelectrophysiological studies. Environ Res (1993) 1.07
Monoclonal antibody-defined human lung cell surface protein antigens. Cancer Res (1982) 1.06
Mouse monoclonal antibodies against human cancer cell lines with specificities for blood group and related antigens. Characterization by antibody binding to glycosphingolipids in a chromatogram binding assay. J Biol Chem (1983) 1.06
Radiographic demonstration of common bile duct varices. Gastrointest Radiol (1982) 1.05
Expression of DR antigens in freshly frozen human tumors. Hybridoma (1982) 1.05
Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B cells fused with murine myeloma. Hybridoma (1982) 1.04
Alteration of cell surfaces with increased tumorigenicity. Arch Immunol Ther Exp (Warsz) (1977) 1.04
Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat Biotechnol (1999) 1.02
Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants. Proc Natl Acad Sci U S A (1985) 1.02
Cytolytic interactions between murine macrophages, tumor cells, and monoclonal antibodies: characterization of lytic conditions and requirements for effector activation. J Immunol (1986) 1.01
Histogenesis of exocrine pancreatic cancer in the hamster model. Environ Health Perspect (1984) 1.01
Effects of sodium pentobarbital anesthesia and neurotrophic factor on the maintenance of acetylcholinesterase and butyrylcholinesterase in the preganglionically denervated superior cervical ganglion of the cat. Proc Natl Acad Sci U S A (1983) 1.00
Establishment of hamster pancreatic ductal carcinoma cell line (PC-1) producing blood group-related antigens. Carcinogenesis (1989) 1.00
Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III are obtained from mice immunized with human tumors. Arch Biochem Biophys (1982) 1.00
Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a phase II trial. Int J Radiat Oncol Biol Phys (1992) 1.00
Identification of melanoma-associated antigens using fixed tissue screening of antibodies. Cancer Res (1984) 0.99
Transdifferentiation of human islet cells in a long-term culture. Pancreas (2001) 0.99
Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys (1983) 0.98
Spontaneous remission of parathyroid adenoma followed with ultrasonographic examinations. J Clin Ultrasound (1994) 0.97
Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). Contraception (2003) 0.97
Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res (1988) 0.97
Production and characterization of monoclonal antibodies against human malignant melanoma. Cancer Invest (1983) 0.96
Development of intrapancreatic transplantable model of pancreatic duct adenocarcinoma in Syrian golden hamsters. Am J Pathol (1991) 0.96
Enhancement of pancreatic carcinogenesis in hamsters fed a high-fat diet ad libitum and at a controlled calorie intake. Cancer Res (1989) 0.96
Expression of nerve growth factors in pancreatic neural tissue and pancreatic cancer. J Histochem Cytochem (2001) 0.95